Long-Awaited Results of Isatuximab Combo in R/R Myeloma Presented

Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs  pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma.

Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news